Global Uveitis Market - 2024–2031
Global Uveitis Market reached US$456 million in 2022 and is expected to reach US$837 million by 2031, growing with a CAGR of 4.80% during the forecast period 2026-2031.
The Global Uveitis Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Uveitis Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Uveitis Type
Both primary and secondary data sources have been used in the global Global Uveitis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Global Uveitis Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Uveitis Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Uveitis Type
- Anterior Uveitis *
- Intermediate Uveitis
- Posterior Uveitis
- Pan Uveitis
- Corticosteroids *
- Betamethasone
- Dexamethasone
- Cortisone
- Triamcinolone
- Methylprednisolone
- Anti-Rheumatic Drugs
- Mycophenolate
- Cyclosporine
- Azathioprine
- Tacrolimus
- Cycloplegic-Mydriatic Drugs
- Tropicamide
- Cyclopentolate
- Phenylephrine
- Homatropine
- Atropine
- Immunomodulatory Therapy
- Methotrexate
- Mycophenolate Mofetil
- Biological Therapy
- Infliximab
- Adalimumab
- Daclizumab
- Interferon-Alfa
- Anti-Viral Drugs
- Aciclovir
- Valaciclovir
- Others
- Eye Drops *
- Pills
- Injections
- Implants
- Hospital Pharmacies *
- Retail Pharmacies
- Online Pharmacies
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Global Uveitis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing product pipeline of pharma companies
4.1.1.2. Rising advancements in technologies leading to the development of new drugs
4.1.2. Restraints:
4.1.2.1. High cost associated with treatment
4.1.2.2. High risk of side effects
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY UVEITIS TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
7.1.2. Market Attractiveness Index, By Uveitis Type
7.2. Anterior Uveitis *
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
7.3. Intermediate Uveitis
7.4. Posterior Uveitis
7.5. Pan Uveitis
8. BY MEDICATIONS
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
8.1.2. Market Attractiveness Index, By Medications
8.2. Corticosteroids *
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
8.2.3. Betamethasone
8.2.4. Dexamethasone
8.2.5. Cortisone
8.2.6. Triamcinolone
8.2.7. Methylprednisolone
8.3. Anti-Rheumatic Drugs
8.3.1. Mycophenolate
8.3.2. Cyclosporine
8.3.3. Azathioprine
8.3.4. Tacrolimus
8.4. Cycloplegic-Mydriatic Drugs
8.4.1. Tropicamide
8.4.2. Cyclopentolate
8.4.3. Phenylephrine
8.4.4. Homatropine
8.4.5. Atropine
8.5. Immunomodulatory Therapy
8.5.1. Azathioprine
8.5.2. Methotrexate
8.5.3. Mycophenolate Mofetil
8.5.4. Cyclosporine
8.6. Biological Therapy
8.6.1. Infliximab
8.6.2. Adalimumab
8.6.3. Daclizumab
8.6.4. Interferon-Alfa
8.7. Anti-Viral Drugs
8.7.1. Aciclovir
8.7.2. Valaciclovir
8.8. Others
9. BY MEDICATION FORM
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
9.1.2. Market Attractiveness Index, By Medication Form
9.2. Eye Drops *
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
9.3. Pills
9.4. Injections
9.5. Implants
10. BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. COMPANY PROFILES
13.1. Novartis AG *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. AbbVie
13.3. Johnson & Johnson Services, Inc.
13.4. Amgen
13.5. Alimera Sciences
13.6. Bausch & Lomb Incorporated.
13.7. Kiora Pharmaceuticals, Inc.
13.8. Santen Pharmaceutical Co., Ltd.
13.9. EyePoint Pharmaceuticals, Inc.
13.10. Clearside Biomedical(*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Medications
14.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing product pipeline of pharma companies
4.1.1.2. Rising advancements in technologies leading to the development of new drugs
4.1.2. Restraints:
4.1.2.1. High cost associated with treatment
4.1.2.2. High risk of side effects
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY UVEITIS TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
7.1.2. Market Attractiveness Index, By Uveitis Type
7.2. Anterior Uveitis *
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
7.3. Intermediate Uveitis
7.4. Posterior Uveitis
7.5. Pan Uveitis
8. BY MEDICATIONS
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
8.1.2. Market Attractiveness Index, By Medications
8.2. Corticosteroids *
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
8.2.3. Betamethasone
8.2.4. Dexamethasone
8.2.5. Cortisone
8.2.6. Triamcinolone
8.2.7. Methylprednisolone
8.3. Anti-Rheumatic Drugs
8.3.1. Mycophenolate
8.3.2. Cyclosporine
8.3.3. Azathioprine
8.3.4. Tacrolimus
8.4. Cycloplegic-Mydriatic Drugs
8.4.1. Tropicamide
8.4.2. Cyclopentolate
8.4.3. Phenylephrine
8.4.4. Homatropine
8.4.5. Atropine
8.5. Immunomodulatory Therapy
8.5.1. Azathioprine
8.5.2. Methotrexate
8.5.3. Mycophenolate Mofetil
8.5.4. Cyclosporine
8.6. Biological Therapy
8.6.1. Infliximab
8.6.2. Adalimumab
8.6.3. Daclizumab
8.6.4. Interferon-Alfa
8.7. Anti-Viral Drugs
8.7.1. Aciclovir
8.7.2. Valaciclovir
8.8. Others
9. BY MEDICATION FORM
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
9.1.2. Market Attractiveness Index, By Medication Form
9.2. Eye Drops *
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
9.3. Pills
9.4. Injections
9.5. Implants
10. BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. COMPETITIVE LANDSCAPE
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. COMPANY PROFILES
13.1. Novartis AG *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. AbbVie
13.3. Johnson & Johnson Services, Inc.
13.4. Amgen
13.5. Alimera Sciences
13.6. Bausch & Lomb Incorporated.
13.7. Kiora Pharmaceuticals, Inc.
13.8. Santen Pharmaceutical Co., Ltd.
13.9. EyePoint Pharmaceuticals, Inc.
13.10. Clearside Biomedical(*LIST NOT EXHAUSTIVE)
14. DATAM INTELLIGENCE
14.1. Appendix
14.2. About Us and Medications
14.3. Contact Us
